Lucid Diagnostics Q3 revenue $1.2M, loss $0.10/share; key Medicare coverage step from unanimous CAC expert support

Lucid Diagnostics Inc.

2025-Q3 EPS reported -$0.59 vs consensus -$0.11 ▼ miss (-424.9%)

Processed 2,841 EsoGuard tests in Q3 2025, revenue $1.2 million.
GAAP net loss $10.4M ($0.10/share); non-GAAP adjusted loss $10.3M ($0.10/share).
Cash $47.3M after $27M public offering; runway extended through 2026.
MolDx CAC meeting on Sept 4: medical experts unanimously supported Medicare coverage for EsoGuard.
Appointed Danielle Scelfo as SVP Market Access to lead payor engagement and coverage expansion.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.